期刊
GASTROENTEROLOGY CLINICS OF NORTH AMERICA
卷 43, 期 3, 页码 525-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.gtc.2014.05.010
关键词
Malignancy; Lymphoma; Skin cancer; Biologics; Inflammatory bowel disease
资金
- AbbVie
- Janssen
- UCB
- Agency for Healthcare Research and Quality [1R01HS021747-01]
In this review, the available data regarding the risk of lymphoma, skin cancers, and other malignancies associated with biological agents that are approved and those under investigation for use in inflammatory bowel disease (IBD) are highlighted. How providers may approach the use of these agents in various clinical scenarios is discussed. This review may help providers better understand the true risk of malignancy associated with these agents, thereby leading to an enhanced communication process with patients with IBD when therapeutic decisions are being made.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据